Press Release NEC- Transgene EN
Month: October 2018
€26.6 million in cash and cash equivalents as of September 30, 2018
20181025 PR Q3-2018 EN
First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors
20181017 PR TG6002 US
Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018
20181010 AASLD Abstract Poster EN
Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference
20181001 SITC Poster VEN